RxDoctor Payments Data

Lisa Rock

Psychiatric/Mental Health · Marshalltown, IANPI 1487908380

Payments from drug & device makers

$2,264in general payments, 2019–2025

Across 116 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$509
  • Otsuka America Pharmaceutical, Inc.$339
  • AbbVie$303
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$244
  • Corium, LLC$196
  • Alkermes, Inc.$144
  • plus $529 from 14 others

What the payments were for

  • Food & beverage$2,264100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,264 in reported general payments places this provider in the 70th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$15,103
Medicare patients
41
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate43$151,260
AristadaAripiprazole Lauroxil17$54,783
VraylarCariprazine Hcl25$37,643
Aripiprazole94$6,022
AzstarysSerdexmethylphen/Dexmethylphen12$5,506
Quetiapine Fumarate ErQuetiapine Fumarate13$4,698
Vilazodone Hcl39$4,225
Duloxetine Hcl118$3,822
Lisdexamfetamine Dimesylate12$2,913
Buspirone Hcl131$1,857
Paliperidone ErPaliperidone14$1,250
Mirtazapine59$1,083
Trazodone Hcl114$979
Quetiapine Fumarate82$910
Venlafaxine Hcl ErVenlafaxine Hcl81$900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$509$151,26043 claims
Alkermes, Inc.Aristada$144$54,78317 claims
AbbVieVraylar$303$37,64325 claims
Corium, LLCAzstarys$196$5,50612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in Marshalltown

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →